Revvity (NYSE:RVTY) Posts Earnings Results, Beats Estimates By $0.05 EPS

Revvity (NYSE:RVTY - Get Free Report) announced its quarterly earnings results on Monday. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.05, Zacks reports. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The firm had revenue of $664.76 million during the quarter, compared to the consensus estimate of $662.30 million. During the same period in the prior year, the company posted $0.98 earnings per share. The firm's quarterly revenue was up 2.3% compared to the same quarter last year. Revvity updated its FY 2025 guidance to 4.900-5.000 EPS.

Revvity Price Performance

Shares of NYSE:RVTY traded up $1.14 during midday trading on Friday, hitting $94.04. 944,884 shares of the stock were exchanged, compared to its average volume of 929,707. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. The company has a 50 day moving average price of $103.23 and a 200-day moving average price of $112.33. Revvity has a twelve month low of $88.53 and a twelve month high of $129.50. The stock has a market cap of $11.30 billion, a P/E ratio of 42.55, a PEG ratio of 3.82 and a beta of 1.07.

Revvity Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 8th. Investors of record on Friday, July 18th will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.30%. The ex-dividend date is Friday, July 18th. Revvity's dividend payout ratio is currently 11.91%.

Wall Street Analyst Weigh In

Several research firms have issued reports on RVTY. UBS Group upgraded shares of Revvity from a "neutral" rating to a "buy" rating and decreased their price objective for the company from $145.00 to $115.00 in a research note on Thursday. Robert W. Baird dropped their price target on Revvity from $127.00 to $125.00 and set an "outperform" rating on the stock in a research note on Tuesday. JPMorgan Chase & Co. reduced their price objective on Revvity from $120.00 to $100.00 and set a "neutral" rating for the company in a research note on Tuesday. KeyCorp increased their price objective on Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Finally, Sanford C. Bernstein cut shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 target price on the stock. in a report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $125.64.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.